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Abstract
This chapter deals with the interactions of two medically important ABC multidrug
transporters (MDR-ABC), ABCB1 and ABCG2, with lipid molecules. Both ABCB1 and
ABCG2 are capable of transporting a wide range of hydrophobic drugs and xenobiotics
and are involved in cancer chemotherapy resistance. Therefore, the exploration of their
mechanism of action has major therapeutic consequences. As discussed here in detail,
both ABCB1 and ABCG2 are significantly affected by various lipid compounds especially
those residing in their close proximity in the plasma membrane. ABCB1 is capable of
transporting lipids and lipid derivatives, and thus may alter the general membrane com-
position by “flopping”membrane lipid constituents, while there is no such information
regarding ABCG2. Still, both ABCB1 and ABCG2 show complex interactions with a variety
of lipid molecules, and the transporters are significantly modulated by cholesterol and
cholesterol derivatives at the posttranslational level. In this chapter, we explore the
molecular details of the direct transporter–lipid interactions, the potential role of
lipid-sensor domains within the proteins, as well as the application of experimental
site-directed mutagenesis, detailed structural studies, and in silico modeling for exam-
ining these interactions. We also discuss the regulation of ABCB1 and ABCG2 expression
at the transcriptional level, occurring through nuclear receptors involved in lipid sens-
ing. The better understanding of lipid interactions with these medically important




dt0010 CMC Au4critical micelle concentration
dt0015 DMPE 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine
dt0020 DPPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
dt0025 ESR electron spin resonance
dt0030 β-MCD β-methyl cyclodextrane
dt0035 MDR-ABC multidrug resistance ATP-binding Cassette
dt0040 NMR nuclear magnetic resonance
dt0045 PC phosphatidylcholine
dt0050 PE phosphatidylethanolamine
dt0055 SDS sodium dodecyl sulfate
s0005 1. INTRODUCTION—THE COMPLEX INTERACTIONS OF
LIPIDS AND ABC MULTIDRUG TRANSPORTERS
p0060 The subjects of this chapter are the interactions of two clinically
important ABC multidrug (MDR-ABC) transporters, ABCB1 (P-gp/
MDR1) and ABCG2 (ABCP/BCRP/MXR), with their membrane lipid
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environment and other lipid molecules. Since several chapters in this book
present detailed descriptions of MDR-ABC transporters, here we only
shortly summarize their main features.
p0065 Both ABCB1 and ABCG2 are glycosylated integral plasma membrane
proteins which are involved in the cellular extrusion of a large variety of
xenobiotics and endobiotics. These ATP-dependent transporters contain
large transmembrane domains (TMDs) composed of alpha helices and sim-
ilarly to all other ABC transporters, cytoplasmic nucleotide-binding
domains (NBDs). In a general mechanism of action, the binding and hydro-
lysis of ATP in the NBDs provide the energy for drug or xenobiotic extru-
sion through the transmembrane regions of the protein. ABCB1 has been
the first recognized plasmamembrane multidrug transporter, which contains
2 NBDs and 2 TMDs with altogether 12 transmembrane helices within 1
polypeptide chain. The ABCG2 protein was discovered only about 15 years
ago and is a “half ABC transporter” containing only one TMD consisting of
six transmembrane helices and one NBD. The functional form of ABCG2
has been shown to be a homodimer or homo-oligomer (Bhatia, Schafer, &
Hrycyna, 2005; Ni, Mark, Cai, & Mao, 2010; Ozvegy et al., 2001; Xu, Liu,
Yang, Bates, & Zhang, 2004).
p0070 Both of these transporters have a “promiscuous” capacity of recognizing
a large number of transported substrates. The ABCB1 protein transports
mostly hydrophobic or positively charged amphipathic molecules, while
the substrate specificity of the ABCG2 transporter is even wider and includes
entirely hydrophobic toxic compounds, amphiphilic positively or negatively
charged, as well as practically water-soluble molecules. Besides their capa-
bility of transporting various therapeutic drugs, these MDR-ABC trans-
porters also play an important physiological role in cellular and systemic
detoxification and are key members of the xenobiotic or the so-called
chemoimmunity defense system of the body (Sarkadi, Homolya,
Szakacs, & Varadi, 2006; Sarkadi, Muller, &Hollo, 1996). Besides its general
protective role, ABCB1 is currently not known to transport any specific
physiological substrates. In contrast, ABCG2 has recently been shown to
be an efficient uric acid transporter and thus plays an important role in urate
metabolism. Polymorphic ABCG2 variants are strongly implicated in the
development of gout (Woodward et al., 2009).
p0075 Both ABCB1 and ABCG2 are preferentially expressed in various tissue
barriers and in the apical/luminal membranes of polarized cells. In cancer
cells, the expression of these MDR-ABC transporters results in cross-
resistance (or multidrug resistance, MDR) against a wide range of
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chemotherapeutic drugs, including practically all available anticancer agents
that have to cross the cell membrane to reach their intracellular targets.
Moreover, normal and cancer stem cells express ABCG2 (and in some cases
ABCB1), and this expression pattern may be an important factor in the
inherent chemotherapy resistance of cancer stem cells.
p0080 As mentioned above, both ABCB1 and ABCG2 reside in the plasma
membrane and in polarized cells are recruited into the apical (luminal) mem-
branes. The mammalian plasma membrane has a complex structure of sev-
eral lipid species in which selected lipids may preferentially surround
membrane proteins. Membrane lipids are known to greatly affect the struc-
ture and function of a number of membrane proteins, especially those inter-
acting with hydrophobic or amphipathic substrates. Even in the cases of
those membrane proteins, e.g., ion channels or hormone receptors, when
the ligands are hydrophilic species, protein conformational changes are
required to transmit the messages or ions through the membrane environ-
ment, and the energetics and speed of this information or material transfer
may be greatly affected by lipid interactions (Laganowsky et al., 2014;
Phillips, Ursell, Wiggins, & Sens, 2009). Basic categories of these physical
and/or chemical interactions are summarized in (Fig. 1). The membrane
effects on integral proteins are amplified by the formation of various lipid
microdomains, depending on lipid compositions, temperature, and
membrane-associated (e.g., cytoskeletal) proteins.
p0085 The annular lipid regions around transmembrane regions of membrane
proteins may directly modulate their activities. The special membrane
domains showing different lipid and protein associations, in most cases
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enriched in sphingomyelin (SM) and cholesterol are often called lipid rafts.
In biological membranes, in contrast to unsaturated glycerophospholipids,
SMs in the outer plasma membrane leaflet in many cases have stretched con-
formations, and this SM conformation allows more intimate contacts with
cholesterol. Also, the larger headgroup of SM may shield the hydrophobic
part of cholesterol fromwater; thus, SM and cholesterol may become closely
packed in a partially ordered phase (Ohvo-Rekila, Ramstedt, Leppimaki, &
Slotte, 2002; vanMeer, Voelker, & Feigenson, 2008). The definition of such
lipid rafts is quite variable and sometimes controversial (Mayor &Rao, 2004;
Munro, 2003; Simons & Gerl, 2010)—biochemists and cell biologists have
somewhat different approaches in this regard. Biochemists regard lipid rafts
as the membrane fractions which are insoluble or less soluble in nonionic
detergents, e.g., Triton X-100, CHAPS, Brij 96, or Lubrol WX
(London & Brown, 2000), although even these different detergents produce
variable “raft” fractions. In this regard, Brij 96 and Lubrol WX have milder
solubilizing potential than Triton X-100 (Schuck, Honsho, Ekroos,
Shevchenko, & Simons, 2003); thus, “Lubrol rafts” may contain different
membrane lipids and proteins than “Triton rafts.” Cell biologists are more
concerned about close proximity selective protein interactions, observed in
20–100 nm wide dynamically organized membrane regions under various
functional conditions, including membrane trafficking, receptor-dependent
signal transduction, channel formation, or substrate transport (see Fig. 1).
p0090 As agreed by both the biochemistry and cell biology approaches, lipid rafts
in the plasma membranes contain most of the glycosylphosphatidylinositol-
anchoredproteins, gangliosides, and flotillin andmaypull together a varietyof
proteins involved in the signal transduction machinery (Pike, 2003).
A specialized type of raft domains is the caveola, characterized by membrane
invaginations stabilized by a hairpin-likemembrane protein, caveolin. Cyto-
skeletal elements at the internal membrane surface may stabilize the rafts and
the included integralmembraneproteins, and such a “membrane scaffold”has
been implicated in numerous membrane protein functions.
p0095 Both ABCB1 and ABCG2 have been reported to reside in detergent-
insoluble rafts (Ismair et al., 2009; Orlowski, Martin, & Escargueil, 2006;
Radeva, Perabo, & Sharom, 2005; Storch, Ehehalt, Haefeli, & Weiss,
2007) and in close interaction with cholesterol and caveolin. In the canalic-
ular membranes of hepatocytes, several ABC transporters, including ABCB4
(MDR3), ABCB11 (BSEP, S-P-gp), ABCC2 (MRP2), and ABCG5/G8,
have also been shown to reside in raft domains (Ismair et al., 2009). The
properties of transmembrane regions of ABC transporters, such as the length
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of transmembrane helices and/or the interaction of transmembrane helices
with cholesterol, may actually favor the localization of these proteins in the
raft domains.
p0100 It is important to note that ABCB1 is in a mutual relationship with its
membrane environment, that is, not only the membrane lipids alter the
function of ABCB1 but this protein may actively modify its lipid environ-
ment (for reviews, see Denning & Beckstein, 2013; Orlowski et al., 2006;
Peetla, Vijayaraghavalu, & Labhasetwar, 2013; Pohl, Devaux, & Herrmann,
2005; Sharom, 2014). ABCG2 is less characterized in this respect, but lipid
interactions certainly affect its function.
p0105 In studying the lipid regulation of ABC membrane transporters, the
selection of proper assay systems is a major hurdle. Since MDR-ABC trans-
porters have key interactions with a wide range of hydrophobic toxins and
drugs, it is inherently difficult to analyze the lipid effects on the actual sub-
strate transport pathway or on the general conformation and activity of the
protein. Clearly, membrane lipid constituents, especially cholesterol, may
act both ways. In whole cell assays, studying drug resistance or direct
drug/xenobiotic extrusion, lipid modulation may be easily recognized by
the altered function of the transporter, but lipid modifications have to be
properly controlled not to cause a general damage of the plasma membrane
composition. Lipid enrichment or extraction methods thought to be selec-
tive may result in a nonspecific permeabilization or a general disruption of
the lipid rafts and/or the associated cytoskeletal elements.
p0110 The key functional assays in isolated cell membrane preparations involve
the measurement of substrate-stimulated ATPase activity and the direct
transport activity of ABCB1 or ABCG2. Although coupling between the
ATPase and drug transport activity is well established, both ABCB1 and
ABCG2 have significant basal ATPase activities even in the absence of drug
substrates. The nature of this basal ATPase activity has not been properly
established. Direct determination of the vesicular uptake of radiolabeled
or fluorescent substrates into inverted membrane vesicles may overcome this
problem. For vesicular transport studies, the lipid-dependent tight sealing of
the vesicles is essential and may be significantly altered by lipid modifica-
tions. Both transporters have a well measurable function especially when
expressed in insect cells, capable of generating large amounts of functional,
membrane-inserted proteins. However, mammalian cell membranes have
five to eight times higher cholesterol levels than the insect cell membranes,
whichmay significantly alter ABC transporter activity. A relatively mild way
of reducing or increasing cell membrane lipids, especially cholesterol, is the
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incubation of the cells with “empty” or lipid-complexed cyclodextrin com-
pounds (Telbisz et al., 2007; Zidovetzki & Levitan, 2007).
p0115 Another suitable assay system for analyzing the ABC transporter and lipid
interactions is based on the preparation of isolated and reconstituted pro-
teins. In this case, the modulation of the lipid composition used for recon-
stitution allows a direct estimation of the lipid effects. However, these
methods are inherently difficult to perform and the activity of the purified
ABC transporter may be significantly affected by the remaining detergent or
lipid content of the reconstituted proteoliposomes (Decottignies,
Kolaczkowski, Balzi, & Goffeau, 1994; Mao, Deeley, & Cole, 2000;
Telbisz et al., 2007).
s0010 2. EFFECTS OF LIPIDS ON THE FUNCTION OF ABCB1
AND ABCG2
s0015 2.1. Localization of ABCB1 and ABCG2 in specialized
membrane domains
p0120 Since the cholesterol–SM-rich “raft” regions are heterogeneous in compo-
sition, size, and timescale of existence (see Section 1), the association of
ABCB1 and ABCG2 with these regions has been examined by a number
of methods.
p0125 ABCB1 has been reported to reside in Triton X-100-resistant rafts
(Ismair et al., 2009; Orlowski et al., 2006) or in Brij 96-resistant rafts
(Radeva et al., 2005), although ABCB1 was found to be an active drug
transporter both in raft and in nonraft regions (Bucher, Besse, Kamau,
Wunderli-Allenspach, & Kramer, 2005). Still, recent studies, examining
the ratio of active state conformations of ABCB1 by the conformation sen-
sitive UIC2 antibody, indicate that this protein may be more active in
cholesterol-rich, caveolin-positive regions and thus may be regulated by fac-
tors altering raft assembly (Bacso et al., 2004). Treatment of cells by
β-methyl cyclodextrin (β-MCD) for cholesterol depletion or the application
of cholesterol-loaded β-MCD for cholesterol enrichment was reported to
modify the transport functions of ABCB1 in several experiments, but in
other reports, no significant effects were observed (Luker, Pica, Kumar,
Covey, & Piwnica-Worms, 2000; Telbisz et al., 2007). This conditional
effect may be dependent on the cell-type and transported substrates exam-
ined. Moreover, the application of high concentrations of β-MCD may
cause significant nonspecific membrane alteration effects and toxicity.
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p0130 ABCG2 was found in Triton X-100-insoluble lipid rafts in close inter-
action with cholesterol and caveolin (Storch et al., 2007). As discussed
below, in the case of ABCG2, cholesterol is an essential modulator of the
transport activity; thus, raft localization may be advantageous for its proper
functioning.
p0135 Most intracellular membranes contain relatively low levels of cholesterol;
thus, ABCB1 and ABCG2 transporter activity may be significantly lower
during membrane protein processing and traveling from the ER and Golgi
to the plasma membrane. Moreover, the apical membranes of polarized cells
contain significantly more cholesterol-rich microdomains (Simons & Gerl,
2010) than the basolateral regions, and this unequal cholesterol distribution
may also result in large differences in transporter activity. Since both ABCB1
and ABCG2 are localized in the apical–luminal compartments in polarized
tissue regions (e.g., in the liver canalicular membranes, in the intestinal or
kidney epithelia), specific local interactions may be important factors in
the lipid regulation of transporter activity in these regions.
s0020 2.2. Substrate handling of ABCB1 and ABCG2 and the role
of membrane lipids
p0140 Hydrophobic molecules accumulate in the lipid phase of the cellular mem-
branes and achieve much higher concentrations within the membranes than
in the cytoplasmic or extracellular water phases. Cholesterol, in addition to
stabilizing membrane structures, may further increase lipid insertion of
hydrophobic drugs or xenobiotics. In addition, amphiphilic, positively
charged drug compounds, e.g., doxorubicin, mitoxantrone, or verapamil,
interact with negatively charged lipid headgroups, while the hydrophobic
parts of these drugs interact with apolar membrane regions (Siarheyeva,
Lopez, & Glaubitz, 2006; Speelmans, Staffhorst, De Wolf, & De Kruijff,
1995). Therefore, membrane lipids might significantly affect the plasma
membrane concentrations and availability of ABCB1 or ABCG2 substrates.
p0145 Practically all of the ABCB1 and most of the ABCG2 substrates are
lipophilic/amphiphilic compounds, and it is by nowwell accepted that these
transporters may gain access to their hydrophobic substrates directly in the
membrane lipid phase (Coleman, Quazi, & Molday, 2013; Sharom, 2014).
Several experimental results indicate that ABCB1 binds its drug substrates
within the plasma membrane and most probably in the inner leaflet of
the plasma membrane (Clay & Sharom, 2013; Higgins & Gottesman,
1992; Sharom, 1997). Drug partitioning into the lipid membrane and drug
binding to ABC multidrug transporters show close correlation (Clay &
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Sharom, 2013; Romsicki & Sharom, 1999). FRET studies, applying a fluo-
rescent substrate drug (doxorubicin) of ABCB1 and a lipophilic fluorescent
compound (iodonaphtalen-1-azide) that can be directly attached to ABCB1
through photoaffinity labeling, indicated drug binding to the transporter
within the lipid phase (Raviv, Pollard, Bruggemann, Pastan, &
Gottesman, 1990).
p0150 In addition, several experimental results imply that both ABCB1 and
ABCG2 can expel extracellularly added hydrophobic compounds from
the cells before these compounds would reach the cytoplasm. In one of these
approaches, ABCB1 was shown to reduce the cellular accumulation of fluo-
rescent indicator dyes. These compounds (e.g., Quin-2, Indo-1, or Fluo-4)
are usually added to the cells in a nonfluorescent acetoxymethylester (AM)
form, and then intracellular esterases produce the fluorescent, free dye com-
pounds. It has been observed that when the ABCB1 protein is expressed in
the cell membrane, the fluorescent dye accumulation is strongly reduced
because the transporter removes the AM compound from the membrane
before the cytoplasmic esterases could produce the fluorescent free dye
(Homolya et al., 1993). Moreover, the active extrusion of calcein-AM, a
dye used earlier as a viability indicator (the free calcein fluorescence is insen-
sitive to cellular ionic environment or pH), allowed the development of a
highly sensitive fluorescent assay for measuring cellular ABCB1 transport
activity (Hollo, Homolya, Davis, & Sarkadi, 1994; Homolya, Hollo,
Muller, Mechetner, & Sarkadi, 1996; Homolya et al., 1993).
p0155 Another detailed study of ABCG2 activity documented that
mitoxantrone, a cytotoxic agent that is highly fluorescent in the lipid phase,
accumulates in the cell membrane but this accumulation is strongly reduced
by the presence and activity of ABCG2. Mathematical modeling based on
detailed cellular microscopy fluorescence measurements further supported a
direct extrusion of mitoxantrone by ABCG2 from the membrane phase
(Homolya, Orban, Csanady, & Sarkadi, 2011).
p0160 Thus, hydrophobic drugs are most probably extruded by ABCB1 and
ABCG2 from the plasma membrane. Two transport models have been pro-
posed to describe this phenomenon, the so-called hydrophobic vacuum
cleaner and the flippase models (see Fig. 2 and Higgins & Gottesman,
1992). In both models, the transported substrate is recognized within the
membrane; however, while according to the “vacuum cleaner” model
the substrate is released to the extracellular water phase, the flippase model
(in recent times modified to “floppase,” based on its outward direction) sug-
gests that drugs are only “flopped” by the transporter from the inner to the
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outer membrane leaflet and then either diffuse to the extracellular water
phase or remain in the outer membrane leaflet. In fact, a significant enrich-
ment in the outer membrane leaflet and a large outward substrate gradient
may produce the same extrusion effect than a direct transport to the extra-
cellular fluid. In the future, a more detailed knowledge on the atomic level
structure of the transporters may help to distinguish between these molec-
ular mechanisms of action.
s0025 2.3. Modulation of ABCB1 and ABCG2 function by lipids,
lipid derivatives, and detergents
p0165 The transport functions of ABCB1 and ABCG2 are significantly affected by
membrane lipids especially by cholesterol, as well as lipid derivatives and
detergent compounds. ABCB1 in fact is able to transport (or flop) various
membrane phospholipids and lipid derivatives (van Helvoort et al., 1996).
There are no available data for phospholipid or phospholipid-derivative
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transport by ABCG2, while cholesterol has been shown to display a signif-
icant effect on this transporter. Still, due to technical limitations, in most
cases, it is difficult to clarify whether a lipid compound is a modulator or
a transported substrate of these MDR-ABC proteins. In many cases, even
direct lipid or detergent interactions cannot be distinguished from indirect
effects, caused by the alteration of the general membrane properties.
p0170 In this chapter, we focus on the interactions of cholesterol and its main
derivatives with ABCB1 and ABCG2.However, it is also worthmentioning
that several steroid hormones and hormone metabolites have been shown to
be transported substrates of these proteins. ABCB1 was indicated to trans-
port progesterone and aldosterone (Kim & Benet, 2004; Ueda et al., 1992),
while ABCG2 is an efficient transporter for hormone derivatives, including
estradiol sulfate and estradiol glucuronide (Suzuki, Suzuki, Sugimoto, &
Sugiyama, 2003).
p0175 Cholesterol depletion of the cell membranes has been reported to
decrease both ABCB1 and ABCG2 function (Storch et al., 2007; Troost,
Lindenmaier, Haefeli, & Weiss, 2004). For assessing a direct modulation
of these transporters by membrane cholesterol, various functional assays
should be combined, e.g., measurement of vanadate-sensitive, basal, or
drug-stimulated ATPase activity, direct drug transport in isolated mem-
branes, or combined ATPase and transport activity by isolated and rec-
onstituted proteins (see Section 1).
p0180 ABCB1 is most probably not directly involved in cholesterol transport
(Tarling, de Aguiar Vallim, & Edwards, 2013), and studies for the cholesterol
modulation of the transporter yielded variable results. ABCB1 ATPase
activity was measured in most cases in native membranes prepared from
ABCB1-overexpressing cells. While the basal ATPase activity of ABCB1
was increased by cholesterol, the substrate-stimulated activity was less mod-
ified (Belli, Elsener, Wunderli-Allenspach, & Kramer, 2009; Bucher, Belli,
Wunderli-Allenspach, & Kramer, 2007). In addition, in the case of smaller
size drug substrates, cholesterol had a much greater influence on the
substrate-dependent ABCB1-ATPase activity than in the case of larger drug
substrates (Kimura, Kioka, Kato, Matsuo, & Ueda, 2007). Thus, the func-
tion of ABCB1 seems to be relatively insensitive to changes in the choles-
terol content of the plasma membrane and the effects of cholesterol largely
depend on the size of the transported substrate (see in detail in Section 4.1.2).
p0185 Although several close relatives in the ABCG subfamily are involved in
steroid transport (ABCG1 transports cholesterol and the ABCG5/G8
heterodimer transports plant sterols), ABCG2 is probably not an active
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cholesterol transporter (Kimura, Kodan, Matsuo, & Ueda, 2007), and no
ABCG2 defects have been associated with cholesterol metabolic diseases.
Still, cholesterol has a major modulatory effect on ABCG2 activity.
p0190 When ABCG2 is expressed in cholesterol-poor insect cell membranes,
the addition of cholesterol in the form of a complex with β-MCD signifi-
cantly stimulates both drug transport and ATPase activity (Pal et al., 2007;
Telbisz et al., 2007). The addition of other sterol compounds, e.g., sitosterol
or ergosterol, has similar effect, although the most effective modulator in
lower concentrations is cholesterol (Telbisz et al., 2007). Experiments per-
formed using isolated ABCG2 strongly indicate that cholesterol or other
membrane sterols are essential cofactors influencing ABCG2 function. In
the case of isolated and reconstituted ABCG2, both ATPase and transport
activity have been shown to be very low in a membrane lipid environment
lacking cholesterol (Telbisz, Ozvegy-Laczka, Hegedus, Varadi, & Sarkadi,
2013). Cholesterol has been shown to increase the basal ATPase activity
of ABCG2 in a concentration-dependent manner; moreover, stimulation
of the ABCG2-ATPase activity by transporter substrates could only be
achieved in the presence of cholesterol (Telbisz et al., 2013).
p0195 The major cholesterol derivatives in the human body are bile salts, and in
some tissues, e.g., in the liver and the intestine, where bile salt concentra-
tions are relatively high, these compounds may significantly affect ABC
transporter function. Since bile acids and derivatives also have strong deter-
gent activity, this feature may also be involved in their functional effects.
p0200 A close homologue of ABCB1, ABCB11 (BSEP/S-P-gp), is the main
bile acid transporter in the liver canalicular membrane, while ABCB1 has
not been shown to be involved in bile acid transport. Substrate transport
by ABCB1 has been reported to be inhibited by bile acids (Mazzanti
et al., 1994), but the detergent effects of bile acids may also explain this
phenomenon.
p0205 The function of ABCG2has been shown to be significantlymodulated by
bile salts and detergents with chemical structures resembling to bile salts (e.g.,
CHAPS) (Telbisz, Hegedus, Varadi, Sarkadi, & Ozvegy-Laczka, 2014;
Telbisz et al., 2013). In isolated ABCG2-containing membranes or in rec-
onstitutedABCG2proteoliposomes, bile salts applied inmuch lowerconcen-
trations than the potential detergent effects strongly decreased the basal
ABCG2-ATPase activitywhilenot affecting the substrate-stimulatedATPase
activity in the presence of cholesterol (Telbisz et al., 2014). Experiments
detailed below indicate that both cholesterol and bile acidsmodulateABCG2
function independently of interacting with the substrate transport sites.
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p0210 Regarding potential bile salt transport by ABCG2, the experimental
results are contradictory. ABCG2 expressed in Lactococcus lactis showed
higher ATPase activity in the presence of certain bile salts and caused aminor
bacterial resistance against bile salt toxicity ( Janvilisri, Shahi, Venter,
Balakrishnan, & van Veen, 2005). In CHO cells, coexpression of rat
Oatp1a1 and human ABCG2 enhanced both the uptake and the efflux of
a fluorescent conjugated bile acid, cholyl-glycylamido-fluorescein, cholic
acid (CA), glycoCA, tauroCA, and taurolithocholic acid-3-sulfate
(Blazquez et al., 2012). In contrast, in our experiments using human
ABCG2-expressing isolated insect membranes, we could not detect any
ATP-dependent vesicular accumulation of radiolabeled bile acids. Under
the same experimental conditions, we could measure substantial vesicular
transport by the known professional bile acid transporters, ABCC2
(MRP2) and ABCB11 (BSEP/S-P-gp) (Telbisz et al., 2014).
p0215 Detergents, by disrupting hydrophobic protein interactions with mem-
brane lipids, in most cases, inhibit ABCB1 and ABCG2 function. Strong
ionic detergents, such as SDS, may irreversibly destroy transporter function.
Still, some nonionic detergents, such as Triton X-100 or C12EO8, below
their CMC concentrations, have been indicated to be transported substrates
of ABCB1 and possibly bind to the drug-binding site of the protein (Beck
et al., 2013; Li-Blatter, Nervi, & Seelig, 2009; Seelig & Gerebtzoff, 2006;
Zordan-Nudo, Ling, Liu, & Georges, 1993). Bile acids and related com-
pounds (e.g., CHAPS) modify ABCG2 transporter function below the con-
centrations causing detergent effects, while some potentially “mild”
detergents may have serious adverse effects. Since functional ABCG2 is a
homodimer, a detergent-induced dissociation of the ABCG2 dimer has
been shown to irreversibly destroy the function of this transporter
(Telbisz et al., 2014).
s0030 2.4. Role of lipids in MDR-ABC protein purification
and reconstitution
p0220 Solubilization, isolation, and reconstitution of large membrane proteins are
in most cases more related to “art” than to simple technologies, and this is
certainly true in the case of MDR-ABC transporters.
p0225 For the solubilization of ABCB1, certain mild detergents, e.g., octyl-
glycoside, dodecyl-maltoside (DDM Au5), or CHAPS, were optimal for pre-
serving ABCB1 activity, possibly by retaining a lipid shell around the protein
(Ambudkar, 1995; Doige, Yu, & Sharom, 1993; Orlowski et al., 1998;
Shapiro & Ling, 1995; Sharom, Yu, & Doige, 1993). Indeed, CHAPS
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molecules were found to be in close association with a partially purified
ABCB1 (Sharom, Yu, Chu, & Doige, 1995). DDM alone was unable to
maintain functionality, but in the presence of lipid additives (e.g., Escherichia
coli lipids) solubilization with this detergent also preserved ABCB1 activity.
p0230 In the process of solubilization and isolation of ABCG2, the choice of
detergents has been proved to be the most important factor to obtain a func-
tional transporter (Telbisz et al., 2013). Purification trials revealed a high
sensitivity of ABCG2 to total delipidation. Therefore, mild solubilization
conditions had to be applied in order to preserve a lipid shell around the sol-
ubilized ABCG2 protein. The homodimeric ABCG2 protein was even
more sensitive to detergents than ABCB1, and the addition of extra lipids
at the solubilization step was indispensable for maintaining activity
(Telbisz et al., 2014).
p0235 Reconstitution studies showed that purified ABCB1 can be functional in
several types of liposomes, composed of different phosphatidylcholine (PC)
and phosphatidylethanolamine (PE) mixtures, and the addition of choles-
terol is not required for full activity (Bucher et al., 2007; Doige et al.,
1993; Kimura, Kioka, et al., 2007; Modok, Heyward, & Callaghan,
2004). ABCB1 was active even in pure DMPE or DPPE liposomes, but
the application of PC:PE mixtures increased activity and unsaturated lipids
also had an activating role (Doige et al., 1993). The analysis of the effects of
the length of lipid side chains revealed an optimum bilayer width, and the
headgroups of the lipids were also found to be important (Sharom, 2014).
p0240 The presence of cholesterol is not necessary for purified ABCB1 activity
in liposomes (Bucher et al., 2007; Kimura, Kioka, et al., 2007), and not only
other sterols but also α-tocopherol or even DPPC caused the samemoderate
effect as cholesterol on the ABCB1 function in PC liposomes (Belli
et al., 2009).
p0245 The purified and reconstituted ABCG2 was found to be inactive in PC:
PE lipid mixtures and had low activity in an E. coli lipid extract, containing
no cholesterol. In contrast, the protein had high activity in cholesterol con-
taining natural lipid extracts, e.g., in brain lipids or in E. coli lipid extract
that was supplemented with cholesterol. The E. coli lipid extract was the
most suitable for examining the sterol dependence of ABCG2 activity,
and these experiments showed that sitosterol or ergosterol can also
activate the ABCG2 protein (Telbisz et al., 2007). In Section 4, we provide
a detailed analysis of the potential molecular interactions between sterols
and ABCG2.
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s0035 2.5. MDR-ABC transporters may actively alter the membrane
lipid environment
p0250 Since ABCB1 and ABCG2 transport hydrophobic compounds, they may
significantly modulate the composition of the plasma membrane around
their residing areas. Several publications revealed differences in the lipid
composition of parental and MDR-ABC-expressing drug-resistant cell line
pairs (Hinrichs, Klappe, & Kok, 2005; Peetla et al., 2013). ABCB1 has
indeed been shown to be capable of the outward transport of NBD labeled
or radiolabeled short PC and PE analogues (Bosch, Dunussi-Joannopoulos,
Wu, Furlong, & Croop, 1997; van Helvoort et al., 1996).
p0255 This transport in whole cells represents a lipid “floppase” activity of the
protein. In liposomes, the purified and reconstituted ABCB1 was also found
to have phospholipid and glycolipid transport activity. In liposomes con-
taining purified ABCB1 in an inverted orientation, an ATP-dependent
transport activity was found when measuring the movement of fluorescent
lipid analogues from outside to the inside of the liposomes. This lipid trans-
port activity was inhibited by ABCB1 drug substrates; thus, drug and lipid
transport activities are similar processes (Eckford & Sharom, 2005;
Romsicki & Sharom, 2001).
p0260 According to data in the literature, ABCB1 can also transport ceramides
and sphingolipids (Clay & Sharom, 2013; Coleman et al., 2013; Radeva
et al., 2005; Sharom, 2014), indicating a wide substrate specificity of ABCB1
also for lipid molecules. This lipid floppase activity can be involved in alter-
ing the cell membranes for drug distribution, thus modifying the multidrug
resistance phenotype even for drugs not directly transported by ABCB1.
A detailed characterization of the potential transport of membrane lipid
derivatives by ABCG2 has not been reported as yet.
s0040 3. EFFECTS OF LIPIDS ON THE EXPRESSION OF ABCB1
AND ABCG2: REGULATION BY NUCLEAR RECEPTORS
p0265 As discussed in the previous sections, lipids can significantly modify
the substrate handling, the ATPase activity, and the transport function of
the ABCB1 and ABCG2 proteins. In addition, an increasing body of evi-
dence suggests that cellular lipid species might also influence the expression
of these MDR-ABC transporters by regulating their gene expression via
nuclear receptors (NRs).
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s0045 3.1. The NR superfamily of transcription factors and
lipid-sensing NRs
p0270 The NR superfamily comprises 48 members in the human genome and rep-
resents the largest currently known family of transcription factors. NRs
work as ligand-activated transcription factors and affect various cellular pro-
cesses such as reproduction, development, and metabolism through regulat-
ing the expression of their target genes. Following the cloning of the first
steroid hormone receptors, the glucocorticoid (GR) and estrogen (ER)
receptors in the mid-1980s, early studies established the fundamental role
of hormone–receptor complexes in transcriptional regulation and endocrine
signaling and surprisingly also revealed the existence of several evolutionarily
related proteins all sharing a common modular structure. The three func-
tional domains shared by NRs are (i) the N-terminal ligand-independent
transactivation domain which is recognized by coactivators and/or other
transcription factors; (ii) the most highly conserved central DNA-binding
domain with two zinc-finger motifs that besides binding to DNA is also
important in NR dimerization; and (iii) the C-terminal ligand-binding
domain which also displays a ligand-induced activation function involved
in transcriptional coregulator interaction. The basic mechanism of transcrip-
tional regulation of the target genes is also shared among the NR family
members: upon ligand binding, the typically cytosolic resident NRs disso-
ciate from their partner proteins, shuttle to the nucleus, and bind to the NR
response elements (derivatives of the canonical sequence RGGTCA termed
as hormone response element where R stands for purine) of the target genes
as monomers, homodimers, or heterodimers, and by recruiting various
coactivator or corepressor complexes modulate transcriptional activity
(Chan, Hoque, & Bendayan, 2013; Evans, 2005; Evans & Mangelsdorf,
2014; Gronemeyer, Gustafsson, & Laudet, 2004).
p0275 Despite the structural similarities, the ligand sensitivity of the different
NRs shows wide variations. According to the ligand-binding specificities,
NRs can be divided into three classes: (i) steroid and endocrine receptors,
(ii) true orphan receptors, and (iii) adopted orphan receptors. Steroid and
endocrine NRs, such as the estrogen receptor (ER) or the progesterone
receptor (PR), were identified through analyzing the effect of known hor-
mones, and this class of NRs represents important mediators of endocrine
signaling. In contrast, orphan receptors have been identified through molec-
ular sequence analysis without any prior knowledge about their ligand spec-
trum, and while the ligands of true orphan receptors are still to be identified,
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adopted orphan NRs have recently been found to be involved in xenobiotic
and in lipid sensing (Chan et al., 2013; Chawla, Repa, Evans, &
Mangelsdorf, 2001; Handschin & Meyer, 2005; Klaassen & Aleksunes,
2010; Wang & LeCluyse, 2003).
p0280 The lipid-sensing adopted orphan NRs include the sterol sensor LXR
(liver X receptor), the bile acid sensor FXR (farnesoid X receptor), the fatty
acid sensor PPAR (peroxisome proliferator-activated receptor). The
xenosensors CAR (constitutive androstane receptor) and PXR/SXR (pre-
gnane X receptor/steroid xenobiotic receptor) can also interact with lipid
ligands (Chawla et al., 2001; Evans & Mangelsdorf, 2014; Handschin &
Meyer, 2005; Ory, 2004). These NRsmust heterodimerize with RXR (ret-
inoid X receptor) to exert their gene regulatory function. The aforemen-
tioned NRs have been reported to be expressed in various tissues,
including the intestine, the liver, and the central nervous system, and notably
show an overlapping tissue expression pattern with several ABC trans-
porters, including ABCB1 and ABCG2 (Chan et al., 2013; Jonker,
Stedman, Liddle, & Downes, 2009).
p0285 Lipid- and xenobiotic-sensing NRs have been implicated in the orches-
trated transcriptional regulation of enzymes and transporters involved
in lipid metabolism or detoxification and thus their action provides a coor-
dinated cellular response to perturbations affecting these processes (Fig. 3)
(Chan et al., 2013; Chawla et al., 2001; Handschin & Meyer, 2005;
Jonker et al., 2009; Ory, 2004; Urquhart, Tirona, & Kim, 2007). Profes-
sional lipid ABC transporters, such as the cholesterol and phospholipid trans-
porter ABCA1, the long-chain PC and cholesterol transporter
ABCB4 (MDR3), the bile salt transporter ABCB11 (BSEP/S-P-gp), or
the major sterol transporters ABCG5/G8 (working as an obligate
heterodimer), have indeed been shown to be regulated by lipid-sensing
NRs (Beyea et al., 2007; Jonker et al., 2009; Schmitz & Langmann,
2005; Tarling et al., 2013; van Meer et al., 2008). Interestingly, to date,
several NRs also involved in the recognition of lipid ligands have been
shown to affect the gene expression of human ABCB1 and ABCG2, the
transport functions of which are mainly involved in causing multidrug resis-
tance (Borst & Elferink, 2002; Jonker et al., 2009; Klaassen & Aleksunes,
2010; Natarajan, Xie, Baer, & Ross, 2012; Sarkadi et al., 2006; Scotto,
2003). Therefore, via binding to and activating their cognate NRs, lipid
molecules might also be directly involved in the transcriptional regulation
of both ABCB1 and ABCG2.
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s0050 3.2. Regulation of the expression of ABCB1 by NRs
p0290 Several NR response elements have been identified in the promoter of the
ABCB1 gene. The 50-upstream enhancer region of ABCB1 was shown to
contain functional PXR- and CAR-binding sites. Upon ligand binding,
both PXR and CAR were reported to induce mRNA expression of the
transporter (Burk, Arnold, Geick, Tegude, & Eichelbaum, 2005;
Cerveny et al., 2007; Geick, Eichelbaum, & Burk, 2001; Saeki, Kurose,
Hasegawa, & Tohkin, 2011; Synold, Dussault, & Forman, 2001). Regula-
tion of ABCB1 gene expression at the mRNA level was also suggested to
occur by the PXR and CAR pathways in cultures of primary human hepa-
tocytes ( Jigorel, Le Vee, Boursier-Neyret, Parmentier, & Fardel, 2006;
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f0015 Figure 3 Regulation of MDR-ABC transporters by nuclear receptors (NRs). Upon binding
their ligands, typically cytosol-resident NRs dissociate from their cytosolic partner pro-
teins (not shown) and translocate to the nucleus where they heterodimerize with RXR
(not shown), recruit various coactivators or corepressors (not shown), and modulate
gene transcription. PXR, CAR, and PPARαAu2 and PPARγ response elements have been iden-
tified in the ABCB1 and ABCG2 gene promoters (see text for details). NRs have also been
implicated in the regulation of lipidmetabolism; therefore, besides direct transcriptional
regulation of ABCB1 and ABCG2, by altering the membrane lipid composition, they
might also be involved in the regulation of MDR-ABC transporter function. NR, nuclear
receptor; PM, plasma membrane.
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Maglich et al., 2002) and also at the human blood–brain barrier (Chan,
Hoque, Cummins, & Bendayan, 2011). In contrast, in the human hepato-
cyte model cell HepG2, and also in rat liver, the lack of involvement of LXR
in the regulation of ABCB1 expression was reported (Chisaki, Kobayashi,
Itagaki, Hirano, & Iseki, 2009).
p0295 It has recently been shown that two other NRs, the thyroid hormone
receptor β (TRβ) and the vitamin D receptor (VDR), also regulate the tran-
scription of ABCB1 via binding as heterodimers with RXRα to the previ-
ously identified 50-upstream enhancer region in the ABCB1 gene promoter
(Kurose, Saeki, Tohkin, & Hasegawa, 2008; Saeki, Kurose, Tohkin, &
Hasegawa, 2008).
s0055 3.3. Regulation of the expression of ABCG2 by NRs
p0300 The promoter of ABCG2 has been reported to contain an overlapping estro-
gen response element and a progesterone response element, which were
shown to specifically bind ERα and progesterone receptor A and
B (PRA and PRB), respectively. Expression of ABCG2 was reported to
be induced by estrogen through ERα; however, enhanced expression of
ABCG2 by progesterone was observed only in model cells expressing
PRB, whereas PRA was shown to repress PRB activity (Ee et al., 2004;
Wang et al., 2008).
p0305 Three functional PPAR response elements were also identified in the
upstream enhancer region of ABCG2, and binding of the PPARγ–RXR
heterodimer to this region was reported to be involved in the direct tran-
scriptional upregulation of ABCG2 in human dendritic cells (Szatmari
et al., 2006) (Fig. 3B). Recently, another isoform, PPARα, has also been
shown to directly induce ABCG2 mRNA and protein expression through
binding to the same conserved enhancer region of the ABCG2 gene in
human brain microvessel endothelial cells (Hoque, Robillard, &
Bendayan, 2012).
p0310 In primary human hepatocytes, exposure to certain NR ligands resulted
in enhanced ABCG2 mRNA expression, strongly suggesting the regulatory
role of the PXR and CAR pathways ( Jigorel et al., 2006). In a following
study, a CAR/RXRα-binding motif in the distal promoter of ABCG2
was identified and, interestingly, ABCG2 transactivation through this motif
was found to occur via CAR but not PXR binding (Benoki, Yoshinari,
Chikada, Imai, & Yamazoe, 2012). In contrast, it has been reported that
LXR agonists do not activate the transcription of ABCG2 either in the
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human hepatocyte cell line HepG2 in vitro or in the rat liver in vivo (Chisaki
et al., 2009).
s0060 3.4. Role of NRs in lipid metabolism and a potential indirect
effect on ABCB1 and ABCG2 transporter function
p0315 As mentioned above, NRs participate in the coordinated regulation of tran-
scriptional programs which can influence overall lipid metabolism (Chawla
et al., 2001; Handschin & Meyer, 2005; Ory, 2004). As detailed in the sec-
tions above Au6, function of the membrane MDR-ABC transporters can signif-
icantly be modified by their membrane lipid environment. Therefore, it is
interesting to note that besides direct regulation of the MDR-ABC gene
transcription, NRs might also exert an indirect regulatory effect on
MDR-ABC function by modulating the levels of lipid species, such as
cholesterol, which are important in maintaining the structures of
biomembranes. According to a recent study, LXR signaling is indeed
involved in the dynamic modulation of membrane lipid composition by
promoting the incorporation of unsaturated fatty acids into phospholipids
in response to changes in cellular lipid metabolism. This LXR-mediated
phospholipid remodeling might affect the biophysical characteristics of bio-
logical membranes and thus might also be involved in the modification of
transmembrane protein function (Rong et al., 2013).
s0065 4. EXPERIMENTAL STRATEGIES TO DEFINE THE
LIPID-INTERACTING REGIONS OF THE ABCB1
AND ABCG2 PROTEINS
p0320 As discussed in Section 2, the activity of ABCB1 and ABCG2 is tightly
regulated by their lipid environment, and their function is practically insep-
arable from the presence of surrounding lipids. Still, the exact nature of this
complex protein–lipid interaction is not fully understood. Furthermore,
protein regions of ABCB1 and ABCG2 responsible for direct interaction
with lipids are not properly mapped, although in recent years numerous
studies have dealt with this question. The main strategies applied in order
to identify the lipid “sensor” regions include site directed mutagenesis of
the transporters, measurements of direct binding of lipids to the proteins,
and molecular dynamics (MD) simulations. In this section, we summarize
the data regarding lipid-sensing regions of ABCB1 and ABCG2 determined
by these techniques.
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p0325 One of the strategies to explore the potential interaction of predicted
proteinmotifs with selected lipids is the alteration of amino acids of the given
region by site-directed mutagenesis. One drawback of this method is that find-
ing the lipid-binding consensus sequences defined by linear peptide
sequences in large proteins is inherently difficult. Still, a systematic, non-
biased mutagenesis approach may circumvent this problem (see below
and Loo, Bartlett, & Clarke, 2009), and also the atomic level structural data
will greatly promote the determination of the lipid-sensing structural pat-
terns. The other limitation of the site directed mutagenesis-based approach
is the difficulty to distinguish between a mutation directly inactivating the
protein, e.g., altering the transport or ATP hydrolytic activity and one selec-
tively altering the cholesterol/lipid sensitivity of the transporter. This uncer-
tainty is caused by the fact that the functions of ABCB1 and ABCG2 are
inseparable from their lipid environment, and there are practically no assays
capable of distinguishing between the aforementioned two phenotypes.
Direct binding studiesmeasuring the interaction between lipids and ABC pro-
teins may provide an independent approach to avoid these problems. How-
ever, as lipids tend to bind to hydrophobic surfaces due to their hydrophobic
nature, this approach necessitates purified ABC proteins and well-chosen
controls to separate specific lipid binding from simple hydrophobic interac-
tions (“sticking”). A detailed description of structural studies-based molecular
simulations for examining MDR-ABC transporter and lipid interactions is
discussed in Section 5.
s0070 4.1. Lipid sensing by the ABCB1 protein
s0075 4.1.1 Mutagenesis studies in ABCB1
p0330 The lipid sensing of ABCB1 has been extensively investigated by mutagen-
esis studies targeting potential amino acids involved in ABCB1–lipid inter-
actions. Since ABCB1 is involved in the transport of lipids and lipid
derivatives (see Section 2), some lipids and related substrates or inhibitors
most probably share the substrate-binding pocket. On the other hand, lipids,
which display modulatory effects and alter function and localization inde-
pendently from substrate binding, most probably interact with the trans-
porter at a different binding site defined by membrane facing amino
acids. Here, we summarize the known lipid-sensing positions in ABCB1
identified by site-directed mutagenesis demonstrating both types of
interactions.
p0335 It has been shown that AdaGb3 (adamantyl globotriaosylceramide), a
water-soluble ganglioside analogue, inhibits ABCB1-mediated vinblastine
Comp. by: S.Anand Stage: Proof Chapter No.: 4 Title Name: ACR
Date:6/11/14 Time:18:14:43 Page Number: 117
117Complex Interaction of Lipids and ABC Multidrug Transporters
ARTICLE IN PRESS
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only
by the author(s), editor(s), reviewer(s), Elsevier and typesetter SPi. It is not allowed to publish this proof online or in print. This proof
copy is the copyright property of the publisher and is confidential until formal publication.
efflux, indicating that the lipid-binding site interferes with substrate binding
(De Rosa et al., 2008). ABCB1 partially colocalizes with
globotriaosylceramide at the cell surface, and glycosphingolipid depletion
results in a decreased cell surface expression of ABCB1, indicating that gan-
gliosides also influence the trafficking of this protein. In order to identify the
positions of the large substrate-binding pocket influencing the binding of
this globotriaosylceramide analogue, De Rosa et al. (2008) introduced cys-
teine pairs into several positions (F343C in TM6, in combination with
F728C in TM7, or Q725C in TM7; and L339C in TM6 with F728C in
TM7) previously demonstrated to be involved in substrate binding (Loo,
Bartlett, & Clarke, 2006). If cross-linking could not be observed between
the two cysteines in the presence of the lipid, then lipid binding at least
to one of the specific amino acid positions was concluded. By applying this
strategy, the authors identified L339C in TM6 to be responsible for AdaGb3
binding.
p0340 With regard to amino acids interacting with the lipid environment but
not involved in direct lipid transport, more extensive data are available. Loo
and Clarke performed numerous studies in order to define amino acids fac-
ing the membrane phase, thus interacting with the lipid environment. In
these studies, a construct with the G251V mutation, causing protein insta-
bility and improper maturation (processing mutant), was used in combina-
tion with Arg mutations in transmembrane helices (Loo, Bartlett, & Clarke,
2008; Loo et al., 2009; Loo & Clarke, 2013). As a result, some “corrector”
mutations rescued the processing mutant G251V by promoting its proper
folding by Loo et al. (2008). The authors hypothesized that when the
inserted Arg faces the lipid interface, the rescue fails because of the intoler-
ability of the positive charge in the hydrophobic environment (see Fig. 4).
Based on the same rationale, Loo and Clarke also performed a large scale
mutagenesis study in which arginines were introduced along all potential
transmembrane helices in ABCB1 (Loo et al., 2009). By using the same
technique, Loo and Clarke also replaced all amino acids found in TM helices
5 and 9. Most of the amino acids identified in their study fit well to the 3D
model built based on the crystal structure of Sav1866; namely these side
chains are looking toward the membrane phase (see Fig. 4). However, some
of the positions identified as lipid-interacting amino acids direct their side
chains toward the substrate-binding cavity and not toward the bilayer
(e.g., in TM10 and 11). One possible explanation for this is that data
obtained from the crystal structure represent only a snapshot; however dur-
ing the catalytic cycle, the protein undergoes major conformational changes
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during which the side chains of the lipid interacting amino acid can face the
membrane phase.
p0345 Recently, relatively detailed atomic level crystal structures have become
available for the homologues of human ABCB1, the Caenorhabditis elegans,
and the mouse Abcb1 proteins (Aller et al., 2009; Jin, Oldham, Zhang, &
Chen, 2012). Thus, proper localization of the amino acids within and out-
side the transmembrane helices can be estimated. Therefore, it can be
expected that these structural data will greatly promote the assignment of
additional lipid-sensing amino acid positions that can be further verified
by site-directed mutagenesis studies.
s0080 4.1.2 Direct binding of lipids and MD simulations on ABCB1
p0350 As discussed above, measurement of lipid binding to the ABCB1 protein can
provide direct data about the protein regions involved in lipid interaction
independently of the substrate transport function. Moreover, lipids inter-
acting with ABCB1 can also be identified by combining lipid binding with
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f0020 Figure 4 Amino acids in ABCB1, facing the lipid interface. The upper view (A) and side
view (B) of the model of the ABCB1 protein created based on the structure of
Sav1866 (Globisch, Pajeva, & Wiese, 2008). Lipid-facing amino acids identified by muta-
genesis studies are indicated by red color (for details see text). Figure is based on Loo
et al. (2009).
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mass spectrometry as demonstrated by Marcoux et al. (2013). They used
purified mouse Abcb1 in a detergent (n-dodecyl-β-D-maltoside—DDM)
containing buffer and analyzed direct lipid binding to Abcb1 and then deter-
mined the bound lipids by mass spectrometry. In this study, three cardiolipin
molecules were found bound to the substrate-binding cavity of Abcb1, and
by related calculations, the size and number of lipids present simultaneously
in the substrate-binding pocket were also determined (Marcoux et al.,
2013). As a further expansion of this study,Marcoux et al. performedmolec-
ular docking in which they showed that cardiolipin-14 binds to K230 and
K822 found in transmembrane helices TM4 and 9 previously shown to be
involved in lipid sensing (see Section 4.1.1).
p0355 The other type of lipids investigated for direct binding to ABCB1 was
cholesterol. Kimura, Kioka, et al. (2007) have shown that cholesterol can
directly bind to purified ABCB1. Additionally, they have systematically ana-
lyzed the effect of cholesterol on the ATP hydrolytic activity of ABCB1.
Cholesterol was observed to activate ATP hydrolysis differently, depending
on the size of the investigated substrate as we discussed earlier. In the case of
small transported molecules (molecular mass below 800 Da), cholesterol
stimulated the ABCB1-ATPase, while cholesterol had no effect on the
ATPase activity in the presence of larger substrates. In the former case, cho-
lesterol altered the substrate KM values, indicating that this lipid directly
interacts with the substrate-binding sites. Based on the alternative effects
of cholesterol on ABCB1 function, the authors devised a cholesterol fill-
in model (see Fig. 5A and B and Kimura, Kodan, et al., 2007), suggesting
that in the case of smaller transported substrates (Fig. 5A), cholesterol can
be present in the cavity simultaneously with the substrate and can promote
the entrance and/or exit of substrate molecules, while in the case of larger
substrates there is no space for cholesterol (Fig. 5B). Later, in the crystal
structure of C. elegans Abcb1 two molecules of a lipid-like substance
(n-undecyl-β-maltoside) were found to be located inside the drug-binding
cavity ( Jin et al., 2012) confirming that lipids can enter the substrate-binding
pocket.
p0360 Besides experimental data, in silico modeling can also be used to deter-
mine protein–lipid interactions. In the case of ABCB1, Wen, Verhalen,
Wilkens, McHaourab, and Tajkhorshid (2013) performed MD simulations.
According to their results, the lipid enters between TM3, 4, and 6 and inter-
acts with Leu-300, Ala-302, Tyr-303, and Ala-338, previously shown to be
involved in drug binding (for details see Section 5).
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s0085 4.2. Lipid sensing by the ABCG2 protein
p0365 In the case of ABCG2, literature for its interaction with lipids is far more
incomplete than in the case of ABCB1. Since no atomic level crystal struc-
ture is available for any closely related ABCG-type proteins, the localization
of amino acids in the transmembrane helices cannot be properly estimated.
The homology models constructed on the basis of unrelated ABC trans-
porters (Hazai & Bikadi, 2008; Li et al., 2007) are contradictory and cannot
be properly applied for devising site-directed mutagenesis.
p0370 Still, information obtained by site-directed mutagenesis and related to
potential lipid sensors and lipid-binding sites in ABCG2 is already available
regarding the interaction of cholesterol and some sterol compounds with the
transporter. As described in Section 2, cholesterol and bile acids have signif-
icant roles in ABCG2 function: ABCG2 is practically inactive in the absence
of cholesterol, while bile acids selectively modulate the basal ATPase activity
of the transporter. In this section, we list the amino acid regions examined in
detail for such sterol interactions.
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f0025 Figure 5 Cholesterol fill-in model for ABCB1 function. In the case of small compounds (A),
cholesterol promotes the transport by filling the substrate-binding pocket, while in the
case of larger substrates (B), the compound itself fills the cavity. Figure is based on the
model of Kimura, Kodan, et al. (2007).
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s0090 4.2.1 Role of the R482 position
p0375 It turned out very early, practically at the cloning of ABCG2 that R482 is a
crucial determinant of substrate recognitionofABCG2. In these early studies,
it was found that amutation ofR482 toGor T occurred in the cell lines upon
anthracycline selection, most probably because these “artificial” (not occur-
ring in vivo) mutant ABCG2 variants results in a “gain-of-function” trans-
porter with increased doxorubicin and rhodamine 123 transport activity
(Chen et al., 2003; Honjo et al., 2001; Miwa et al., 2003; Ozvegy,
Varadi, & Sarkadi, 2002). Later it turned out that amino acid 482 is also
involved in the cholesterol and bile acid sensing of the protein. Interestingly,
Telbisz et al. (2007) found that in contrast to the wild-type protein, the
R482Gmutant is fully active in Sf9 insectmembrane vesicles containing only
low levels of cholesterol (see Section 2). Therefore, ABCG2-R482G seemed
to function in a cholesterol-independent way. Surprisingly, when the iso-
lated, purified, and reconstituted ABCG2-R482Gmutant was characterized
in proteoliposomes, providing a well-controlled lipid environment, it was
found that this mutant also required cholesterol for its activity. Moreover,
themutant variant had an increased cholesterol affinity, that is themutant var-
iant was fully active at much lower cholesterol concentrations in the
proteoliposomes than that required for the wild-type protein (see Fig. 6A
and Telbisz et al., 2013). This finding explained the apparent cholesterol
insensitivity of the R482 mutant in the Sf9membranes, which contain only
low level of sterols thatwere already sufficient toprovide fullABCG2activity.
p0380 Recently, amino acid position 482 was further analyzed in detail with
regard to its influence on the cholesterol-sensing of ABCG2 (Telbisz
et al., 2014). In their study, Telbisz et al. found that replacement of
R482 to smaller amino acids (D, N, S, and T) resulted in a cholesterol-
independent behavior of these mutant proteins in Sf9 insect membranes.
In contrast, larger size amino acids (I, K, M, and Y) produced similar cho-
lesterol sensitivity as the wild-type protein. However and surprisingly, the
wild-type protein proved to be unique in regard with its modulation by bile
acids. All R482 mutants, even those with larger amino acid side chains,
behaved differently from the wild-type transporter (Fig. 6B).
s0095 4.2.2 Role of the LxxL motif
p0385 In several sterol-binding proteins (e.g., progesterone, androgen, estrogen, or
glucocorticoid receptors and oxysterol-binding protein-related proteins), an
LxxLxxL motif (x standing for any amino acid) was identified as a
steroid-binding element (Im, Raychaudhuri, Prinz, & Hurley, 2005;
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f0030 Figure 6 Different positions involved in the sterol-sensing of ABCG2. (A) The R482G
mutant is fully active at lower cholesterol levels. ATPase activity measurement in puri-
fied ABCG2 (wild type and the R482G mutant) reconstituted in proteoliposomes
providesAu8 an excellent tool to investigate ABCG2 activity in a well-controlled lipid envi-
ronment. This experiment shows that in the case of the R482G mutant, both the basal
and the substrate (quercetin)-stimulated ATPase activities are more sensitive to choles-
terol than those of the wild-type protein (Telbisz et al., 2013). (B) The bile-acid modu-
lation of wild-type ABCG2 is unique. In Sf9 insect membranes containing wtABCG2
(R482), the relative substrate stimulation of the ATPase activity is significantly higher
in the presence of bile acids. When R482 is mutated, the effect of bile acids is greatly
decreased.
(Continued)
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Williams & Sigler, 1998). Although this is a relatively nonconserved
sequence, in ABCG2, only a shorter LxxL motif (amino acids 555–558)
can be found (Fig. 6C), which has been examined in detail as a potential lipid
interactive or sensor region.
p0390 Velamakanni, Janvilisri, Shahi, andvanVeen(2008) by expressing ABCG2
in L. lactis found that the L555A/L558A mutant loses its progesterone and
estradiol recognition capacity. In another study, Telbisz et al. (2014)
observed that in Sf9 membranes the L555A and L558A mutants behaved
in a cholesterol-independent manner. However, in proteoliposomes, the
L558A mutant also required cholesterol for its ATPase activity. Unfortu-
nately, the L555A/L558A mutant could not be investigated in its purified
and reconstituted form because an inactivation due to loss of dimerization
occurred during purification. This latter observation may indicate that cho-
lesterol promotes proper membrane insertion and the formation of the
ABCG2 homodimer, and the double mutant becomes nonfunctional
because of the loss of lipid sensing in this protein region.
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f0030 Figure 6—Cont'dca 030 (C) Positions of amino acids involved in sterol sensing of ABCG2. The
topology of ABCG2 has been determined using HMMTOP (Tusnady & Simon, 2001) and
drawn by using http://emboss.bioinformatics.nl/cgi-bin/emboss/topo. Amino acids
involved in lipid sensing are indicated. Panel (B): Adapted from Telbisz et al. (2014).
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s0100 4.2.3 Role of the CRAC motif
p0395 Several conserved motifs have already been experimentally shown to be
involved in cholesterol sensing in “professional” cholesterol-binding
proteins. These motifs include the sterol-sensing domain comprising five
transmembrane helices, the YIYF sequence, the CRAC (cholesterol
recognition amino acid consensus), and the CARC (“inverted” CRAC)
motifs (Baier, Fantini, & Barrantes, 2011; Epand, 2006). In the case of
ABCG2, the potential role of the CRAC motif (L/V-X1–5-Y-X1–5-R/
K, X standing for any amino acid) has recently been analyzed in detail by
site-directed mutagenesis (Ga´l et al., 2014). In this work, the central, con-
served tyrosines were mutated in five potential CRAC motifs in ABCG2,
and the effects of single mutants on the cholesterol-sensing capability of
ABCG2were analyzed. Interestingly, it was found that three of the five posi-
tions analyzed were important in proper protein folding, while Y413 found
in the predicted TMhelix 1 (Fig. 6C) caused increased cholesterol sensitivity
of the protein.
p0400 As a conclusion, mutagenesis studies performed on ABCG2 provided
variable results, and in some cases, the opposite effect was observed to what
was expected. Both the R482G and the Y413S mutants which were
expected to eliminate sterol binding actually increased the apparent affinity
of the transporter for cholesterol. The experimental examination of the
CRAC motifs also provided only incomplete information; thus, additional
studies are required to map the lipid interacting parts of ABCG2. Until now,
no direct lipid-binding experiments have been performed in the case of this
transporter.
s0105 5. IN SILICOMODELING OF THE LIPID INTERACTIONS OF
ABCB1 AND ABCG2
p0405 Experimental atomic level exploration of the lipid–protein interac-
tions is challenging. Various spectroscopic methods, including NMR and
ESR, have been employed to study these interactions, but provided infor-
mation mostly on average orientational order (Marsh & Pali, 2013). Crystal
structures of membrane proteins obtained by X-ray crystallography in
numerous cases contain associated lipid molecules. However, the orienta-
tion and conformation of the lipids in the crystals are indicated to be different
from that in a lipid bilayer (Marsh & Pali, 2013). As alternative methodol-
ogies, computational approaches can be applied to describe lipid–protein
interactions at the atomic level.
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p0410 All the computational methods discussed here, such as MD simulation or
in silico docking, require high-resolution 3D structure of the protein under
investigation. While murine Abcb1 has been crystallized in an apo state
(Aller et al., 2009), and sufficient homology models can be built for its
ATP-bound conformation (Globisch et al., 2008; O’Mara & Tieleman,
2007; Pajeva, Globisch, & Wiese, 2009), structural or homology models of
humanABCG2are insufficient for in silico studies becauseof the low-resolution
structure information (cryoelectron microscopy, >5 A˚) (Rosenberg et al.,
2010) and the very low (<20%) sequence similarity of the TMD with any
existing ABC structure that could be applied as a possible template.
s0110 5.1. MD simulation
p0415 MD computer simulations attempt to describe the time-dependent move-
ments and interactions of the atoms in the examined protein and its close
environment by numerically solving the equations of molecular mechanics
force fields. Thus, MD simulations for a transmembrane protein in a lipid
bilayer may be suitable to describe conformational changes within the pro-
tein and the movements of the lipids around the protein (Tieleman et al.,
2006). When a lipid molecule interacts with a specific region of the protein,
it “sticks” there and usually interacts with specific amino acids for the
remaining part of the simulation. However, the timescale of the MD sim-
ulations with a large system containing all atoms of all relevant molecules is
highly limited, and the association of a lipid with a specific region of the pro-
tein is a relatively rare event.
p0420 Wen et al. (2013) have performed MD simulations using the mouse
Abcb1 (P-gp) structure (PDB:3G5U) in the apo conformation, with the
NBDs apart. Since the dynamics and lipid interactions in the simulations
may be affected by the initial lipid contacts of the protein, they have gen-
erated four different systems with the protein differently embedded in a
bilayer built from POPE, for parallel simulations. In the case of one of
the four systems, in 50-ns long simulations, the protrusion of a lipid mole-
cule into the cleft between TM4 and 6 could be observed. These TM helices
delineate the putative drug entry site into the central cavity of the protein
(Aller et al., 2009). As ABCB1 has been indicated to possess lipid transport
activity and its drug substrates are hydrophobic, this protrusion event has
been suggested to be equivalent with the initial steps of drug binding.
p0425 To overcome the limitation of the simulation time scale, coarse-grained
(CG) models can be applied to simplify the system under investigation
(Ding, Buldyrev, & Dokholyan, 2005; Klein & Shinoda, 2008;
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Marrink & Tieleman, 2013). In the case of CG models, several atoms are
represented by a single bead (virtual atom) in a way to preserve the topology
and physicochemical properties of the coarse-grained molecule. As an
example, the most widely used MARTINI model (Marrink & Tieleman,
2013), on average maps four heavy atoms and associated hydrogens to a sin-
gle interaction center. In addition, four main interaction types are defined,
such as apolar, nonpolar, polar, and charged. As an example, four water mol-
ecules can be mapped to one CG water bead, and one ion is mapped to a
charged bead that also represents the first hydration shell. However, this type
of mapping is insufficient for describing complex chemical entities, includ-
ing ring-like structures. When a higher resolution mapping is applied, the
force fields of the CG models to describe the interactions between the beads
are parametrized in a systematic way: (1) nonbonded interactions are tuned
to reproduce experimental partitioning free energies between polar and
apolar phases of various chemical compounds, and (2) bonded interactions
are defined and calculated by using reference all-atom simulations.
p0430 A prominent example to decipher lipid–protein interaction by
employing CGMDs has been provided by Schmidt et al., studying the pho-
sphatidylinositol 4,5-bisphosphate (PIP2) binding to the Kir2.2 inwardly
rectifying potassium channel (Schmidt, Stansfeld, Tucker, & Sansom,
2013). At the first stage, they performed coarse-grained simulations with
Kir2.2 and PIP2 placed in a distance from each other in a bilayer. These sim-
ulations and events at this level are sufficiently fast to observe PIP2 diffusion
and association with the potassium channel. At the second stage, the simpli-
fied model of the associated complex and bilayer was converted to all-atom
model for simulations with higher accuracy. Their results, when compared
to experimental data, suggest that multiscale approaches involving coarse-
grained models may properly describe protein–lipid interactions, thus could
be also applied to investigate ABC protein and lipid interactions.
s0115 5.2. In silico docking
p0435 A different approach to study molecular interactions is in silico docking of
small molecules to target proteins. In this case, the protein is usually handled
as a rigid molecule, in contrast to the small molecule that is allowed to rotate
at its bonds. However, docking of lipids is challenging because of their high
rotational freedom (bonds of the hydrophobic chains), that impair the per-
formance of most docking algorithms. Docking of ligands with high number
of atoms is often prohibited even in commercial software. Moreover, the
location of the docking, namely the volume of the search place, is also
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limited and requires a priori knowledge about the binding site. A recently
developed free tool, Autodock Vina (Trott &Olson, 2010), can handle flex-
ible molecules with high number of rotatable bonds and allows to perform
docking in short time with no serious restrictions on putative binding
locations.
p0440 In a recent study, binding of drugs and cardiolipins with different sizes to
the ABCB1 protein has been investigated by using mass spectrometry and
molecular docking (Marcoux et al., 2013). Importantly, the computational
and experimental results were concordant, and the presence of two mole-
cules of the smaller cardiolipin CL14 or only one molecule of the larger
CL24 was indicated in the internal binding pocket of ABCB1. The docking
of the ligands was performed in two steps: (1) simulation with Patchdock
(Schneidman-Duhovny, Inbar, Nussinov, & Wolfson, 2005), employing
a shape complementary criteria; (2) accurate refinement of the orientation
of side chain and ligand atoms, using FireDock (Mashiach, Schneidman-
Duhovny, Andrusier, Nussinov, & Wolfson, 2008).
p0445 As a summary, application of computational methods for studying
lipid–protein interactions is relatively sparse, because of the limitation of the
available tools and the experimental difficulties that make it challenging to
correlate theoretical and experimental results. However, for resolving several
questions, at the atomic level, currently only the in silicomethods are available.
Careful application of these approaches may provide valuable information on
the effects of lipids on MDR-ABC protein stability and conformation.
s0120 6. CONCLUSIONS
p0450 ABCB1 and ABCG2 are two major plasma membrane ABC
multidrug transporters (MDR-ABC) involved in cancer chemotherapy
resistance; thus, the exploration of their mechanism of action has a major
therapeutic consequence. Both ABCB1 and ABCG2 are significantly mod-
ulated by various lipid compounds, especially those residing in the plasma
membrane in their close proximity. In this chapter, we discuss the complex
interactions of ABCB1 and ABCG2 with a variety of lipid molecules, focus-
ing on the role of cholesterol and cholesterol derivatives. We demonstrate
that lipids may affect MDR-ABC function at the transcriptional level,
mainly by interacting with NRs. We also discuss lipid regulation of the
MDR-ABC transporters at the posttranslational level and explore the
molecular details of the direct transporter–lipid interactions, the exploration
of potential lipid-sensor domains. Interestingly, these MDR-ABC proteins
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may also directly influence the general membrane composition, by
“flopping” membrane lipid constituents. The further application of exper-
imental site-directed mutagenesis, detailed structural studies, and in silico
modeling should allow a more detailed understanding of the lipid interac-
tions with these medically important MDR-ABC transporters.
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